Physician profile
Zeba Sami
NPI 1295889046
$9,520.74
in general payments reported to CMS, 2019-2025
27 companies · $1,587 in 2025
The $1,587 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $518 · 2021: $883 · 2022: $1,381 · 2023: $1,602 · 2024: $2,089 · 2025: $1,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,278.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,224.31 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,133.98 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $1,105.01 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,097.01 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $898.72 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $891.55 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $660.84 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $614.67 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $568.59 | 2019-2025 | Spravato, Invega Sustenna |
| Allergan, INC. | $334.29 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $185.47 | 2020-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $172.70 | 2019 | |
| Corium, LLC | $126.76 | 2022-2023 | Azstarys |
| Indivior INC. | $115.82 | 2022-2024 | Perseris, Sublocade |
| Tris Pharma INC | $63.84 | 2023-2025 | Dyanavel Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $63.78 | 2023-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $41.63 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $40.52 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $39.47 | 2023-2024 | Quviviq |
| Sage Therapeutics, LLC | $24.42 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $24.42 | 2025 | Qelbree |
| Shire North American Group INC | $17.52 | 2019 | |
| Braeburn INC. | $16.87 | 2025 | Brixadi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Owp Pharmaceuticals, INC. | $16.50 | 2020 | |
| Adlon Therapeutics L.P. | $12.91 | 2021 | |
| Bausch Health US, LLC | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeba Sami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.